Information Provided By:
Fly News Breaks for January 13, 2020
Jan 13, 2020 | 09:36 EDT
Goldman Sachs analyst Salveen Richter says the global collaboration and license agreement between Incyte (INCY) and MorphoSys (MOR) to develop and commercialize tafasitamab for B-cell malignancies is an "incremental positive" for Incyte, as it adds a near commercial stage asset. Under the terms of the deal, the companies will co-commercialize tafasitamab with a 50:50 profit split in the U.S., while Incyte will have exclusive commercialization rights excluding the U.S. Outside of the initial indication, Incyte and MorphoSys will also explore monotherapy use of tafasitamab in other B cell malignancies as well as in combination with Incyte's parsaclisib, which Richter says offers upside to his numbers. He made no change to his Conviction Buy rating and $107 price target for Incyte shares.
News For INCY;MOR From the Last 2 Days
Feb 16, 2020 | 15:57 EST
Specialty Pharma Analyst Chen, Biotech Analysts Young & Merle, along with Key Opinion Leaders Dr. Goldberg, Skin Laser & Surgery Specialists of NY & NJ and Dr. Weinberg, Forest Hills Dermatology Group, discuss the competitive landscape in atopic dermatitis at a Group Luncheon Meeting being held at Cantor's New York offices on February 24 at 12 pm.